
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 0-19437

ASENSUS SURGICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

1 TW Alexander Drive, Suite 160, Durham, NC 27703
(Address of principal executive offices) (Zip Code)

11-2962080
(I.R.S. Employer
Identification No.)

Registrant's telephone number, including area code: (919) 765-8400

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No .

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No .

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Non-accelerated filer

Accelerated Filer
Smaller reporting company
Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes No

Securities registered pursuant to Section 12(b) of the Act:

| <u>Title of each class</u> | <u>Trading symbol</u> | <u>Name of each exchange on which registered</u> |
|---|-----------------------|--|
| Common Stock \$0.001 par value per share | ASXC | NYSE American |

The number of shares outstanding of the registrant's common stock, as of August 5, 2022 was 236,718,923.

ASENSUS SURGICAL, INC.

TABLE OF CONTENTS FOR FORM 10-Q

| | | |
|----------|---|----|
| PART I. | FINANCIAL INFORMATION | |
| Item 1. | Financial Statements | |
| | Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) | 2 |
| | Condensed Consolidated Balance Sheets (unaudited) | 3 |
| | Condensed Consolidated Statements of Stockholders' Equity (unaudited) | 4 |
| | Condensed Consolidated Statements of Cash Flows (unaudited) | 5 |
| | Notes to Condensed Consolidated Financial Statements (unaudited) | 6 |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 17 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 23 |
| Item 4. | Controls and Procedures | 24 |
| PART II. | OTHER INFORMATION | 24 |
| Item 1. | Legal Proceedings | 24 |
| Item 1A. | Risk Factors | 24 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 24 |
| Item 3. | Defaults Upon Senior Securities | 24 |
| Item 4. | Mine Safety Disclosures | 24 |
| Item 5. | Other Information | 24 |
| Item 6. | Exhibits | 25 |
| | SIGNATURES | 26 |

FORWARD-LOOKING STATEMENTS

In addition to historical financial information, this report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this report, including statements regarding future events, our future financial performance, our future business strategy and the plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “in the event that,” “may,” “plans,” “potential,” “predicts,” “should” or “will” or the negative of these terms or other comparable terminology. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements, including the impact of the coronavirus (COVID-19) pandemic on our operating results. Readers are urged to carefully review and consider the various disclosures made by us, which attempt to advise interested parties of the risks, uncertainties, and other factors that affect our business, operating results, financial condition and stock price, including without limitation the disclosures made under the captions “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Financial Statements,” “Notes to Condensed Consolidated Financial Statements” and “Risk Factors” in this report, as well as the disclosures made in the Asensus Surgical, Inc. Annual Report on Form 10-K for the year ended December 31, 2021 (the “Fiscal 2021 Form 10-K”), and other filings we make with the SEC. Furthermore, such forward-looking statements speak only as of the date of this report. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations except as required by applicable law. To the extent that our business is negatively impacted due to a variety of factors, including the impact of COVID-19 and other geopolitical factors on our operating results, we may implement longer-term cost reduction efforts in order to mitigate such impact. References in this report to “we,” “our,” “us,” or the “Company” refer to Asensus Surgical, Inc., including its subsidiaries Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à.r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc.

Any disclosure in this report regarding the receipt of CE Mark or Section 510(k) clearance for any of the Company’s products does not mean or infer any endorsement of the Company’s products by any government agency including, without limitation, the U.S. Food and Drug Administration, or FDA.

PART 1. FINANCIAL INFORMATION
Item 1. Financial Statements

Asensus Surgical, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands except per share amounts)
(Unaudited)

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|---|--------------------------------|--------------------|------------------------------|--------------------|
| | 2022 | 2021 | 2022 | 2021 |
| Revenue: | | | | |
| Product | \$ 254 | \$ 363 | \$ 601 | \$ 1,726 |
| Service | 424 | 406 | 732 | 785 |
| Lease | 316 | 333 | 727 | 674 |
| Total revenue | <u>994</u> | <u>1,102</u> | <u>2,060</u> | <u>3,185</u> |
| Cost of revenue: | | | | |
| Product | 883 | 1,003 | 1,259 | 2,678 |
| Service | 646 | 636 | 1,141 | 1,002 |
| Lease | 818 | 708 | 1,770 | 1,779 |
| Total cost of revenue | <u>2,347</u> | <u>2,347</u> | <u>4,170</u> | <u>5,459</u> |
| Gross loss | <u>(1,353)</u> | <u>(1,245)</u> | <u>(2,110)</u> | <u>(2,274)</u> |
| Operating Expenses: | | | | |
| Research and development | 7,253 | 4,089 | 13,681 | 8,304 |
| Sales and marketing | 3,602 | 3,562 | 7,321 | 6,615 |
| General and administrative | 4,992 | 3,848 | 10,525 | 7,840 |
| Amortization of intangible assets | 2,533 | 2,862 | 5,203 | 5,729 |
| Change in fair value of contingent consideration | (598) | 478 | (752) | 735 |
| Property and equipment impairment | 432 | - | 432 | - |
| Total Operating Expenses | <u>18,214</u> | <u>14,839</u> | <u>36,410</u> | <u>29,223</u> |
| Operating Loss | <u>(19,567)</u> | <u>(16,084)</u> | <u>(38,520)</u> | <u>(31,497)</u> |
| Other Income (Expense), net | | | | |
| Gain on extinguishment of debt | - | 2,847 | - | 2,847 |
| Change in fair value of warrant liabilities | - | - | - | (1,981) |
| Interest income | 260 | 79 | 515 | 131 |
| Interest expense | (141) | (5) | (341) | (12) |
| Other expense, net | (86) | (7) | (232) | (36) |
| Total Other Income (Expense), net | <u>33</u> | <u>2,914</u> | <u>(58)</u> | <u>949</u> |
| Loss before income taxes | <u>(19,534)</u> | <u>(13,170)</u> | <u>(38,578)</u> | <u>(30,548)</u> |
| Income tax (expense) benefit | <u>(85)</u> | <u>(2)</u> | <u>(169)</u> | <u>36</u> |
| Net loss | <u>(19,619)</u> | <u>(13,172)</u> | <u>(38,747)</u> | <u>(30,512)</u> |
| Comprehensive loss: | | | | |
| Net loss | <u>(19,619)</u> | <u>(13,172)</u> | <u>(38,747)</u> | <u>(30,512)</u> |
| Foreign currency translation (loss) gain | <u>(1,713)</u> | <u>472</u> | <u>(2,363)</u> | <u>(1,466)</u> |
| Unrealized loss on available-for-sale investments | <u>(144)</u> | <u>-</u> | <u>(696)</u> | <u>-</u> |
| Comprehensive loss | <u>\$ (21,476)</u> | <u>\$ (12,700)</u> | <u>\$ (41,806)</u> | <u>\$ (31,978)</u> |
| Net loss per common share attributable to common stockholders - basic and diluted | <u>\$ (0.08)</u> | <u>\$ (0.06)</u> | <u>\$ (0.16)</u> | <u>\$ (0.14)</u> |
| Weighted average number of shares used in computing net loss per common share - basic and diluted | <u>236,505</u> | <u>233,250</u> | <u>236,201</u> | <u>219,199</u> |

See accompanying notes to unaudited condensed consolidated financial statements.

Asensus Surgical, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share amounts)
(Unaudited)

| | June 30, 2022 | December 31, 2021 |
|--|-------------------|----------------------|
| Assets | | |
| Current Assets: | | |
| Cash and cash equivalents | \$ 10,844 | \$ 18,129 |
| Short-term investments, available-for-sale | 83,360 | 80,262 |
| Accounts receivable, net | 699 | 749 |
| Inventories | 8,451 | 8,634 |
| Prepaid expenses | 2,927 | 3,255 |
| Employee retention tax credit receivable | 1,147 | 1,311 |
| Other current assets | 1,134 | 957 |
| Total Current Assets | 108,562 | 113,297 |
| Restricted cash | 1,290 | 1,154 |
| Long-term investments, available-for-sale | 9,581 | 37,435 |
| Inventories, net of current portion | 7,258 | 7,074 |
| Property and equipment, net | 9,389 | 10,971 |
| Intellectual property, net | 4,122 | 9,892 |
| Net deferred tax assets | 244 | 288 |
| Operating lease right-of-use assets, net | 4,747 | 5,348 |
| Other long-term assets | 2,157 | 1,014 |
| Total Assets | \$ 147,350 | \$ 186,473 |
| Liabilities and Stockholders' Equity | | |
| Current Liabilities: | | |
| Accounts payable | \$ 3,849 | \$ 3,448 |
| Accrued employee compensation and benefits | 3,127 | 3,559 |
| Accrued expenses and other current liabilities | 1,617 | 1,617 |
| Operating lease liabilities - current portion | 579 | 683 |
| Deferred revenue | 510 | 543 |
| Total Current Liabilities | 9,682 | 9,850 |
| Long-Term Liabilities: | | |
| Contingent consideration | 1,619 | 2,371 |
| Noncurrent operating lease liabilities | 4,610 | 5,006 |
| Total Liabilities | 15,911 | 17,227 |
| Commitments and Contingencies (Note 14) | | |
| Stockholders' Equity: | | |
| Common stock \$0.001 par value, 750,000,000 shares authorized at June 30, 2022 and December 31, 2021; 236,620,415 and 235,218,552 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively | 237 | 235 |
| Preferred stock, \$0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at June 30, 2022 and December 31, 2021 | - | - |
| Additional paid-in capital | 958,646 | 954,649 |
| Accumulated deficit | (824,121) | (785,374) |
| Accumulated other comprehensive loss | (3,323) | (264) |
| Total Stockholders' Equity | 131,439 | 169,246 |
| Total Liabilities and Stockholders' Equity | \$ 147,350 | \$ 186,473 |

See accompanying notes to unaudited condensed consolidated financial statements.

Asensus Surgical, Inc.
Condensed Consolidated Statements of Changes in Stockholders' Equity
(in thousands)
(Unaudited)

| | Common Stock | | Treasury Stock | | Additional Paid -in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) | Total Stockholders' Equity |
|--|----------------|---------------|----------------|--------|-----------------------------------|------------------------|--|----------------------------------|
| | Shares | Amount | Shares | Amount | | | | |
| Balance, December 31, 2021 | 235,219 | \$ 235 | - | \$ - | \$ 954,649 | \$ (785,374) | \$ (264) | \$ 169,246 |
| Stock-based compensation | - | - | - | - | 2,245 | - | - | 2,245 |
| Exercise of stock options | 30 | - | - | - | 12 | - | - | 12 |
| Award of restricted stock units | 1,166 | 1 | - | - | - | - | - | 1 |
| Return of common stock to pay withholding taxes on restricted stock | - | - | 436 | - | (349) | - | - | (349) |
| Cancellation of treasury stock | - | - | (436) | - | - | - | - | - |
| Other comprehensive loss | - | - | - | - | - | - | (1,202) | (1,202) |
| Net loss | - | - | - | - | - | (19,128) | - | (19,128) |
| Balance, March 31, 2022 | 236,415 | \$ 236 | - | \$ - | \$ 956,557 | \$ (804,502) | \$ (1,466) | \$ 150,825 |
| Stock-based compensation | - | - | - | - | 2,083 | - | - | 2,083 |
| Exercise of stock options | 13 | - | - | - | 6 | - | - | 6 |
| Award of restricted stock units | 192 | 1 | - | - | - | - | - | 1 |
| Other comprehensive loss | - | - | - | - | - | - | (1,857) | (1,857) |
| Net loss | - | - | - | - | - | (19,619) | - | (19,619) |
| Balance, June 30, 2022 | 236,620 | \$ 237 | - | \$ - | \$ 958,646 | \$ (824,121) | \$ (3,323) | \$ 131,439 |
| Balance, December 31, 2020 | 116,231 | \$ 116 | - | \$ - | \$ 781,397 | \$ (722,912) | \$ 2,968 | \$ 61,569 |
| Stock-based compensation | - | - | - | - | 1,786 | - | - | 1,786 |
| Issuance of common stock, net of issuance costs | 70,666 | 71 | - | - | 129,251 | - | - | 129,322 |
| Exercise of stock options and warrants | 45,114 | 45 | - | - | 32,687 | - | - | 32,732 |
| Award of restricted stock units | 706 | 1 | - | - | - | - | - | 1 |
| Return of common stock to pay withholding taxes on restricted stock | - | - | 67 | - | (214) | - | - | (214) |
| Cancellation of treasury stock | - | - | (67) | - | - | - | - | - |
| Other comprehensive loss | - | - | - | - | - | - | (1,938) | (1,938) |
| Net loss | - | - | - | - | - | (17,340) | - | (17,340) |
| Balance, March 31, 2021 | 232,717 | \$ 233 | - | \$ - | \$ 944,907 | \$ (740,252) | \$ 1,030 | \$ 205,918 |
| Stock-based compensation | - | - | - | - | 1,842 | - | - | 1,842 |
| Issuance of common stock, net of issuance costs | 332 | - | - | - | 992 | - | - | 992 |
| Exercise of stock options and warrants | 508 | - | - | - | 337 | - | - | 337 |
| Award of restricted stock units | 674 | 1 | - | - | - | - | - | 1 |
| Return of common stock to pay withholding taxes on restricted stock | - | - | 246 | - | (829) | - | - | (829) |
| Cancellation of treasury stock | - | - | (246) | - | - | - | - | - |
| Other comprehensive gain | - | - | - | - | - | - | 472 | 472 |
| Net loss | - | - | - | - | - | (13,172) | - | (13,172) |
| Balance, June 30, 2021 | 234,231 | \$ 234 | - | \$ - | \$ 947,249 | \$ (753,424) | \$ 1,502 | \$ 195,561 |

See accompanying notes to unaudited condensed consolidated financial statements.

Asensus Surgical, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)

| | Six Months Ended June 30, | |
|--|----------------------------------|-------------|
| | 2022 | 2021 |
| Operating Activities: | | |
| Net loss | \$ (38,747) | \$ (30,512) |
| Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: | | |
| Depreciation | 1,720 | 1,585 |
| Amortization of intangible assets | 5,203 | 5,729 |
| Amortization of discounts and premiums on investments, net | 444 | - |
| Stock-based compensation | 4,328 | 3,628 |
| Gain on extinguishment of debt | - | (2,847) |
| Deferred tax expense (benefit) | 169 | (36) |
| Bad debt expense | 9 | - |
| Change in inventory reserves | (567) | 288 |
| Property and equipment impairment | 432 | - |
| Loss on disposal of property and equipment | 97 | - |
| Change in fair value of warrant liabilities | - | 1,981 |
| Change in fair value of contingent consideration | (752) | 735 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (8) | 127 |
| Inventories | (1,933) | (1,687) |
| Operating lease right-of-use assets | 409 | (2,970) |
| Prepaid expenses | 189 | 517 |
| Other current and long-term assets | (1,169) | 2,660 |
| Accounts payable | 524 | 679 |
| Accrued expenses | (284) | (1,428) |
| Deferred revenue | (4) | 14 |
| Operating lease liabilities | (290) | 3,052 |
| Net cash and cash equivalents used in operating activities | (30,230) | (18,485) |
| Investing Activities: | | |
| Purchase of available-for-sale investments | (17,792) | - |
| Proceeds from maturities of available-for-sale investments | 41,408 | - |
| Purchase of property and equipment | (443) | (700) |
| Net cash and cash equivalents provided by (used in) investing activities | 23,173 | (700) |
| Financing Activities: | | |
| Proceeds from issuance of common stock, net of issuance costs | - | 130,314 |
| Taxes paid related to net share settlement of vesting of restricted stock units | (349) | (1,041) |
| Proceeds from exercise of stock options and warrants | 18 | 30,835 |
| Net cash and cash equivalents (used in) provided by financing activities | (331) | 160,108 |
| Effect of exchange rate changes on cash and cash equivalents | 239 | (329) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (7,149) | 140,594 |
| Cash, cash equivalents and restricted cash, beginning of period | 19,283 | 17,529 |
| Cash, cash equivalents and restricted cash, end of period | \$ 12,134 | \$ 158,123 |
| Supplemental Disclosure for Cash Flow Information | | |
| Cash paid for leases | \$ 549 | \$ 539 |
| Cash paid for taxes | \$ 65 | \$ 50 |
| Supplemental Schedule of Non-cash Investing and Financing Activities: | | |
| Transfer of inventories to property and equipment | \$ 724 | \$ 1,243 |
| Acquisition of property and equipment in accounts payable | \$ - | \$ 67 |
| Reclass of warrant liability to common stock and additional paid-in-capital | \$ - | \$ 2,236 |
| Lease liabilities arising from obtaining right-of-use assets | \$ - | \$ 3,461 |

See accompanying notes to unaudited condensed consolidated financial statements.

Asensus Surgical, Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

1. Description of the Business

Asensus Surgical, Inc. (formerly known as TransEnterix, Inc.) (the "Company") is a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The Company is focused on the market development for and commercialization of the Senhance® Surgical System, which digitizes laparoscopic minimally invasive surgery, or MIS. The Senhance System is the first and only digital, multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including 3mm microlaparoscopic instruments, 5mm articulating instruments, eye-sensing camera control and fully-reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") and include the accounts of the Company and its direct and indirect wholly owned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation. The results reported in these unaudited interim condensed consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for any subsequent period or for the entire year. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto included in the Fiscal 2021 Form 10-K. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in the accompanying interim condensed consolidated financial statements. In the opinion of the Company's management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting only of normal recurring adjustments, except as otherwise indicated, necessary for a fair statement of its financial position, results of operations, and cash flows of the Company for all periods presented.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à.r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc. All inter-company accounts and transactions have been eliminated in consolidation.

Risk and Uncertainties

The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: negative impacts on the Company's operations caused by the COVID-19 pandemic and other geopolitical factors; the historical lack of profitability; the Company's ability to raise additional capital; the success of its market development efforts; its ability to successfully develop, clinically test and commercialize its products; the timing and outcome of the regulatory review process for its products; changes in the health care and regulatory environments of the United States, the European Union, Japan, Taiwan, and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic surgical devices; and its ability to identify and pursue development of additional products.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include impairment considerations for long-lived assets, fair value estimates related to contingent consideration, stock compensation expense, revenue recognition, accounts receivable reserves, short-term and long-term investments, excess and obsolete inventory reserves, inventory classification between current and non-current, measurement of lease liabilities and corresponding right-of-use ("ROU") assets, and deferred tax asset valuation allowances.

Significant Accounting Policies

There have been no new or material changes to the significant accounting policies discussed in the Company's audited financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

Reclassifications

Certain amounts reported previously have been reclassified to conform to current year presentation, with no effect on stockholders' equity or net loss as previously reported. These reclassifications relate to revenue and cost of revenue for leases which historically were included in product and service revenue and corresponding cost of revenue on the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2021.

Impact of Recently Issued Accounting Standards

In June 2016, the Financial Accounting Standards Board ("FASB"), issued ASU 2016-13, *Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*, which is designed to provide financial statement users with more information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. The Company adopted ASU 2016-13 as of January 1, 2022, on a modified retrospective basis. The cumulative-effect adjustment related to the adoption was not material.

In August 2020, the FASB issued ASU 2020-06, *Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815-40)* guidance on the accounting for convertible debt instruments and contracts in an entity's own equity. The guidance simplifies the accounting for convertible instruments by reducing the various accounting models that can require the instrument to be separated into a debt component and equity component or derivative component. The Company adopted ASU 2020-06 as of January 1, 2022. The adoption did not have a material impact to the consolidated financial statements.

The Company has evaluated all other issued and ASUs not yet adopted and believes the adoption of these standards will not have a material impact on its condensed consolidated statements of operations and comprehensive loss, balance sheets, or statements of cash flows.

3. Revenue Recognition

The following table presents revenue disaggregated by type and geography:

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|--------------------------------|------------------------------------|-------------|----------------------------------|-------------|
| | 2022 | 2021 | 2022 | 2021 |
| | (in thousands) | | (in thousands) | |
| U.S. | | | | |
| Systems | \$ - | \$ - | \$ - | \$ 3 |
| Instruments and accessories | 18 | 79 | 82 | 141 |
| Services | 75 | 104 | 149 | 202 |
| Leases | 51 | 91 | 164 | 181 |
| Total U.S. revenue | 144 | 274 | 395 | 527 |
| Outside of U.S. ("OUS") | | | | |
| Systems | - | - | - | 921 |
| Instruments and accessories | 236 | 284 | 519 | 661 |
| Services | 349 | 302 | 583 | 583 |
| Leases | 265 | 242 | 563 | 493 |
| Total OUS revenue | 850 | 828 | 1,665 | 2,658 |
| Total | | | | |
| Systems | - | - | - | 924 |
| Instruments and accessories | 254 | 363 | 601 | 802 |
| Services | 424 | 406 | 732 | 785 |
| Leases | 316 | 333 | 727 | 674 |
| Total revenue | \$ 994 | \$ 1,102 | \$ 2,060 | \$ 3,185 |

Remaining Performance Obligations

Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to service obligations performed under the Company's system sales contracts that will be invoiced and recognized as revenue in future periods. Transaction price allocated to remaining performance obligations as of June 30, 2022 was \$2.1 million, which is expected to be recognized over one to four years.

Contract Assets and Liabilities

The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue for the periods presented was primarily related to service obligations, for which the service fees are billed up-front, generally annually. The associated deferred revenue is generally recognized ratably over the service period. The Company did not have any significant impairment losses on its contract assets for the periods presented. Revenue recognized for the three months ended June 30, 2022 and 2021 that was included in the deferred revenue balance at the beginning of each reporting period was \$0.3 million and \$0.2 million, respectively. Revenue recognized for the six months ended June 30, 2022 and 2021 that was included in the deferred revenue balance at the beginning of each reporting period was \$0.5 million and \$0.4 million, respectively.

The following information summarizes the Company's contract assets and liabilities:

| | As of | |
|------------------|-----------------------|--------------------------|
| | June 30, 2022 | December 31, 2021 |
| | (in thousands) | |
| Contract Assets | \$ 57 | \$ 91 |
| Deferred Revenue | \$ 510 | \$ 543 |

Senhance System Leasing

The Company enters into operating lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the option to purchase the leased System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the System. For the three and six months ended June 30, 2022, and 2021, variable lease revenue related to usage-based arrangements was not material.

Trade Accounts Receivable

The allowance for doubtful accounts is based on the Company's assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay. The allowance for doubtful accounts was \$1.5 million and \$1.7 million as of June 30, 2022, and December 31, 2021, respectively. For the three and six months ended June 30, 2022, and 2021, bad debt expense was not material.

4. Fair Value

The following are categories of assets and liabilities measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):

| June 30, 2022 | | | | |
|---|---|--|--|-------------------|
| (in thousands) | | | | |
| Description | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total |
| Assets measured at fair value | | | | |
| Cash and cash equivalents ⁽¹⁾ | \$ 10,844 | \$ - | \$ - | \$ 10,844 |
| Restricted cash | 1,290 | - | - | 1,290 |
| Short-term investments | - | 83,360 | - | 83,360 |
| Long-term investments | - | 9,581 | - | 9,581 |
| Total assets measured at fair value | \$ 12,134 | \$ 92,941 | \$ - | \$ 105,075 |
| Liabilities measured at fair value | | | | |
| Contingent consideration | \$ - | \$ - | \$ 1,619 | \$ 1,619 |
| Total liabilities measured at fair value | \$ - | \$ - | \$ 1,619 | \$ 1,619 |

⁽¹⁾ Includes investments that are readily convertible to cash with original maturities of 90 days or less.

| December 31, 2021 | | | | |
|---|---|--|--|-------------------|
| (in thousands) | | | | |
| Description | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total |
| Assets measured at fair value | | | | |
| Cash and cash equivalents ⁽¹⁾ | \$ 18,129 | \$ - | \$ - | \$ 18,129 |
| Restricted cash | 1,154 | - | - | 1,154 |
| Short-term investments | - | 80,262 | - | 80,262 |
| Long-term investments | - | 37,435 | - | 37,435 |
| Total assets measured at fair value | \$ 19,283 | \$ 117,697 | \$ - | \$ 136,980 |
| Liabilities measured at fair value | | | | |
| Contingent consideration | \$ - | \$ - | \$ 2,371 | \$ 2,371 |
| Total liabilities measured at fair value | \$ - | \$ - | \$ 2,371 | \$ 2,371 |

⁽¹⁾ Includes investments that are readily convertible to cash with original maturities of 90 days or less.

The carrying values of accounts receivable, other current assets, accounts payable, and accrued expenses and other current liabilities as of June 30, 2022, and December 31, 2021, approximate their fair values due to the short-term nature of these items.

The Company's financial liabilities consisted of contingent consideration payable to an assignee of Sofar, S.p.A., the seller, related to the Company's 2015 acquisition of the Senhance Surgical System (the "Senhance Acquisition"). Adjustments associated with the change in fair value of contingent consideration are included in the Company's condensed consolidated statements of operations and comprehensive loss.

The following table presents quantitative information about the inputs and valuation methodologies used for the Company's fair value measurements for contingent consideration utilizing a Monte-Carlo simulation as of June 30, 2022 and December 31, 2021:

| Valuation Methodology | Significant Unobservable Input | June 30, 2022 | December 31, 2021 |
|----------------------------------|---|----------------------|------------------------------|
| Contingent consideration | Probability weighted income approach | | |
| | Milestone dates | 2031 | 2031 |
| | Discount rate | 14.5% | 9.5% |
| | Revenue volatility | 40.0% | 39.0% |
| | EUR-to-USD exchange rate | 1.05 | 1.14 |

The following table summarizes the change in fair value, as determined by Level 3 inputs for the contingent consideration for the six months ended June 30, 2022 and 2021:

| | Fair Value Measurement at Reporting Date (Level 3) | |
|------------------------------|---|---------------------------------|
| | (in thousands) | |
| | Series B Warrants | Contingent consideration |
| Balance at December 31, 2021 | \$ - | \$ 2,371 |
| Change in fair value | - | (752) |
| Balance at June 30, 2022 | <u>\$ -</u> | <u>\$ 1,619</u> |
| Balance at December 31, 2020 | \$ 255 | \$ 3,936 |
| Exercise of warrants | (2,236) | - |
| Change in fair value | 1,981 | 257 |
| Balance at June 30, 2021 | <u>\$ -</u> | <u>\$ 4,193</u> |
| Current portion | \$ - | - |
| Long-term portion | - | 1,619 |
| Balance at June 30, 2022 | <u>\$ -</u> | <u>\$ 1,619</u> |

5. Investments, available-for-sale

The aggregate fair values of investment securities along with unrealized gains and losses determined on an individual investment security basis and included in other comprehensive loss are as follows:

| | June 30, 2022 | | | | | |
|-------------------|-----------------------|------------------------|------------------------|-------------------|-------------------------------|------------------------------|
| | (in thousands) | | | | | |
| | Amortized Cost | Unrealized Gain | Unrealized Loss | Fair Value | Short-term investments | Long-term investments |
| Commercial Paper | \$ 35,643 | \$ - | \$ (191) | \$ 35,452 | \$ 35,452 | \$ - |
| Corporate Bonds | 58,242 | - | (753) | 57,489 | 47,908 | 9,581 |
| Total Investments | <u>\$ 93,885</u> | <u>\$ -</u> | <u>\$ (944)</u> | <u>\$ 92,941</u> | <u>\$ 83,360</u> | <u>\$ 9,581</u> |

| | December 31, 2021 | | | | | |
|-------------------|--------------------------|------------------------|------------------------|-------------------|-------------------------------|------------------------------|
| | (in thousands) | | | | | |
| | Amortized Cost | Unrealized Gain | Unrealized Loss | Fair Value | Short-term investments | Long-term investments |
| Commercial Paper | \$ 50,705 | \$ - | \$ (46) | \$ 50,659 | \$ 50,660 | \$ - |
| Corporate Bonds | 67,239 | 1 | (202) | 67,038 | 29,602 | 37,435 |
| Total Investments | <u>\$ 117,944</u> | <u>\$ 1</u> | <u>\$ (248)</u> | <u>\$ 117,697</u> | <u>\$ 80,262</u> | <u>\$ 37,435</u> |

The following table summarizes the contractual maturities of the Company's available-for-sale investments:

| | June 30, 2022 | |
|------------------------------|-----------------------|-------------------|
| | (in thousands) | |
| | Amortized Cost | Fair Value |
| Mature in less than one year | \$ 84,173 | \$ 83,360 |
| Mature in one to two years | 9,712 | 9,581 |
| Total | <u>\$ 93,885</u> | <u>\$ 92,941</u> |

Actual maturities may differ from contractual maturities because certain borrowers have the right to call or prepay certain obligations. There were no sales of investments or gross realized gains or losses for the six months ended June 30, 2022, and 2021, respectively.

6. Inventories

The components of inventories are as follows:

| June 30, 2022 | | | |
|--------------------------|--------------------------------------|------------------------|------------------------------------|
| (in thousands) | | | |
| | Gross Carrying Amount | Reserve Balance | Net Carrying Amount |
| Finished goods | \$ 14,687 | \$ (2,931) | \$ 11,756 |
| Raw materials | 6,137 | (2,184) | 3,953 |
| Total inventories | \$ 20,824 | \$ (5,115) | \$ 15,709 |
| Current Portion | \$ 10,113 | \$ (1,662) | \$ 8,451 |
| Long-term portion | 10,711 | (3,453) | 7,258 |
| Total inventories | \$ 20,824 | \$ (5,115) | \$ 15,709 |

| December 31, 2021 | | | |
|--------------------------|--------------------------------------|------------------------|------------------------------------|
| (in thousands) | | | |
| | Gross Carrying Amount | Reserve Balance | Net Carrying Amount |
| Finished goods | \$ 13,066 | \$ (2,987) | \$ 10,079 |
| Raw materials | 8,324 | (2,695) | 5,629 |
| Total inventories | \$ 21,390 | \$ (5,682) | \$ 15,708 |
| Current Portion | \$ 9,931 | \$ (1,297) | \$ 8,634 |
| Long-term portion | 11,459 | (4,385) | 7,074 |
| Total inventories | \$ 21,390 | \$ (5,682) | \$ 15,708 |

The Company has determined that its December 31, 2021 and March 31, 2022 inventory footnote presentation overstated raw materials and understated finished goods by approximately \$2.5 million. For comparative purposes, the Company's prior year inventory footnote has been revised to reflect the adjustment to raw materials and finished goods. The revision had no effect on the previously reported total gross and net carrying value of inventory. The revision also had no effect on the previously reported balance sheets, statements of operations and comprehensive loss, cash flows and stockholders' equity.

7. Intellectual Property

The components of gross intellectual property, accumulated amortization, and net intellectual property are as follows:

| June 30, 2022 | | | | |
|------------------------------------|--------------------------------------|-------------------------------------|--|------------------------------------|
| (in thousands) | | | | |
| | Gross Carrying Amount | Accumulated Amortization | Foreign Currency Translation Impact | Net Carrying Amount |
| Developed technology | \$ 68,838 | \$ (64,094) | \$ (812) | \$ 3,932 |
| Technology and patents purchased | 400 | (220) | 10 | 190 |
| Total intellectual property | \$ 69,238 | \$ (64,314) | \$ (802) | \$ 4,122 |

| December 31, 2021 | | | | |
|------------------------------------|--------------------------------------|-------------------------------------|--|------------------------------------|
| (in thousands) | | | | |
| | Gross Carrying Amount | Accumulated Amortization | Foreign Currency Translation Impact | Net Carrying Amount |
| Developed technology | \$ 68,838 | \$ (58,912) | \$ (262) | \$ 9,664 |
| Technology and patents purchased | 400 | (199) | 27 | 228 |
| Total intellectual property | \$ 69,238 | \$ (59,111) | \$ (235) | \$ 9,892 |

The weighted average remaining useful life of the developed technology and technology and patents purchased was 2.0 years and 4.8 years, respectively, as of June 30, 2022.

8. Leases

Lessee Information

The Company determines if an arrangement contains a lease or service contract at inception. Where an arrangement contains a lease, the Company determines if it is an operating lease or a finance lease. Subsequently, if the arrangement is modified, the Company reevaluates the classification. The Company has entered into operating leases for corporate office buildings, vehicles, and machinery and equipment. Some of the lease agreements have renewal options, tenant improvement allowances, rent escalation clauses, and assignment and subletting clauses. While the operating leases range from one year to ten years, some include options to extend the lease generally between one year and six years, and some include options to terminate the leases within one year.

Components of operating lease expense are primarily recorded in general and administrative on the condensed consolidated statements of operations and comprehensive loss were as follows:

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|-------------------------------|-----------------------------|---------------|---------------------------|---------------|
| | 2022 | 2021 | 2022 | 2021 |
| | (in thousands) | | (in thousands) | |
| Long-term Operating | \$ 386 | \$ 485 | \$ 785 | \$ 923 |
| Short-term Operating | - | - | - | - |
| Total Operating lease expense | <u>\$ 386</u> | <u>\$ 485</u> | <u>\$ 785</u> | <u>\$ 923</u> |

Supplemental balance sheet information related to operating leases was as follows:

| | June 30, 2022 | | December 31, 2021 | |
|--|---------------|--------|-------------------|-------|
| Weighted-average remaining lease term (in years) | 7.4 | | 7.8 | |
| Weighted-average discount rate | 7.4% | | 7.8% | |
| Incremental borrowing rate | 6.1% | - 8.5% | 6.1% | - 8.5 |

Maturities of operating lease obligations as of June 30, 2022 were as follows (in thousands):

| Fiscal Year | |
|--|-----------------|
| 2022 | \$ 430 |
| 2023 | 972 |
| 2024 | 886 |
| 2025 | 881 |
| 2026 | 822 |
| Thereafter | 2,958 |
| Total minimum lease payments | <u>\$ 6,949</u> |
| Less: Amount of lease payments representing interest | <u>(1,760)</u> |
| Present value of future minimum lease payments | <u>\$ 5,189</u> |

9. Property and Equipment Impairment

During the three and six months ended June 30, 2022, the Company recorded a non-cash asset impairment charge of \$0.4 million to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment is associated with returned Senhance Systems under operating leases that are not expected to generate future cash flows sufficient to recover their net book value. The fair value was estimated based on the discounted cash flows expected to be produced by the property and equipment. The impairment was recorded in property and equipment impairment on the condensed consolidated statements of operations and comprehensive loss.

10. Income Taxes

Income taxes have been accounted for using the asset and liability method in accordance with ASC 740 "Income Taxes". The Company computes its interim provision for income taxes by applying the estimated annual effective tax rate method. The Company estimates an annual effective tax rate of (0.4)% for the year ending December 31, 2022. This rate does not include the impact of any discrete items. The Company's effective tax rate for the three months ended June 30, 2022 and 2021 was (0.4)% and 0.0%, respectively. The Company's effective tax rate for the six months ended June 30, 2022 and 2021 was (0.4)% and 0.1%, respectively.

The Company incurred losses for the three and six months ended June 30, 2022, and is forecasting additional losses through the year, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2022. Due to the Company's history of losses, there is not sufficient evidence to record a net deferred tax asset associated with the U.S., Luxembourg, Swiss, Italian, Taiwanese, and Canadian operations. Accordingly, a full valuation allowance has been recorded related to the net deferred tax assets in those jurisdictions.

The total tax (expense) benefit during the three months ended June 30, 2022 and 2021, was approximately (\$0.1) million and (\$0.002) million, respectively. The total tax (expense) benefit during the six months ended June 30, 2022 and 2021, was approximately (\$0.2) million and \$0.036 million, respectively.

At June 30, 2022 the Company had no unrecognized tax benefits that would affect the Company's effective tax rate.

The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income ("GILTI"), states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI as a period expense in the year the tax is incurred. The Company does not expect a GILTI inclusion for 2022; no GILTI tax has been recorded for the six months ended June 30, 2022 or 2021.

11. Stock-Based Compensation

Stock Options

The following table summarizes the Company's stock option activity, including grants to non-employees, for the six months ended June 30, 2022:

| | Number of Shares | Weighted- Average Exercise Price | Weighted-Average Remaining Contractual Term (Years) |
|------------------------------|---------------------|--|--|
| Balance at December 31, 2021 | 4,640,660 | \$ 6.64 | 5.66 |
| Granted | 2,555,396 | 0.77 | |
| Forfeited | (23,047) | 3.22 | |
| Cancelled | (16,983) | 33.27 | |
| Exercised | (43,453) | 0.41 | |
| Balance at June 30, 2022 | <u>7,112,573</u> | <u>\$ 4.52</u> | <u>5.71</u> |

The following table summarizes information about stock options outstanding at June 30, 2022:

| | Number of Shares | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value (Millions) |
|---|---------------------|--|--|--|
| Exercisable at June 30, 2022 | 3,119,355 | \$ 8.02 | 5.08 | \$ - |
| Vested or expected to vest at June 30, 2022 | 6,777,170 | \$ 4.67 | 5.67 | \$ - |

Restricted Stock Units

The following is a summary of the restricted stock units activity, including performance restricted stock units, for the six months ended June 30, 2022:

| | Number of Restricted Stock Units Outstanding | Weighted- Average Grant Date Fair Value |
|----------------------------|---|--|
| Unvested December 31, 2021 | 3,839,030 | \$ 2.36 |
| Granted | 6,040,915 | 0.75 |
| Vested | (1,794,623) | 2.47 |
| Forfeited | (100,047) | 1.36 |
| Unvested Jun 30, 2022 | <u>7,985,275</u> | <u>\$ 1.13</u> |

Performance Restricted Stock Units

In 2022 and 2021, the Company granted performance-based restricted stock units with vesting terms based on our attainment of certain operational targets by October 1, 2023 and October 1, 2022, respectively. The number of shares earnable under the 2022 and 2021 awards are based on achieving designated corporate goals.

Stock-based Compensation Expense

The following table summarizes non-cash stock-based compensation expense by award type for the three and six months ended June 30, 2022, and 2021:

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|------------------------------------|------------------------------------|-----------------|----------------------------------|-----------------|
| | 2022 | 2021 | 2022 | 2021 |
| | (in thousands) | | (in thousands) | |
| Stock options | \$ 924 | \$ 1,087 | \$ 1,901 | \$ 2,207 |
| Restricted stock units | 822 | 690 | 1,707 | 1,293 |
| Performance restricted stock units | 337 | 33 | 720 | 70 |
| | <u>\$ 2,083</u> | <u>\$ 1,810</u> | <u>\$ 4,328</u> | <u>\$ 3,570</u> |

As of June 30, 2022, the Company had future employee stock-based compensation expense of approximately \$3.6 million related to unvested stock options, which is expected to be recognized over an estimated weighted-average period of 2.0 years. As of June 30, 2022, the unrecognized stock-based compensation expense related to unvested restricted stock units was approximately \$6.0 million, which is expected to be recognized over a weighted average period of approximately 1.8 years.

The fair value of options granted were estimated using the Black-Scholes-Merton option pricing model based on the assumptions in the table below:

| | Six Months Ended June 30, | | | |
|--------------------------|----------------------------------|---------|-------------|---------|
| | 2022 | | 2021 | |
| Expected dividend yield | 0% | | 0% | |
| Expected volatility | 128% | - 133% | 118% | - 136% |
| Risk-free interest rate | 1.25% | - 2.98% | 0.33% | - 0.58% |
| Expected life (in years) | 4.3 | - 4.5 | 3.8 | - 4.5 |

12. Equity Offerings

Equity financing transactions for the six months ended June 30, 2021, include:

2020 ATM Offering. On October 9, 2020, the Company filed a prospectus supplement relating to an at-the-market offering with Cantor pursuant to which the Company could sell from time to time, at its option, up to an aggregate of \$40.0 million of shares of the Company's common stock (the "2020 ATM Offering"). The Company terminated this agreement in January 2021.

January 2021 Public Offering. On January 29, 2021, the Company completed an underwritten public offering of 26,545,832 shares of its common stock, including the underwriter's full exercise of an over-allotment option on February 1, 2021, at the public offering price of \$3.00 per share, generating net proceeds of approximately \$73.4 million.

January 2021 Registered Direct Purchase Agreement. On January 12, 2021, the Company sold in a registered direct offering 25,000,000 shares of common stock at a purchase price per share of \$1.25 for aggregate net proceeds of \$28.6 million.

2021 ATM Offering. On May 19, 2021, the Company entered into a Controlled Equity Offering Sales Agreement (the “2021 Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), Robert W. Baird & Co. Incorporated (“Baird”) and Oppenheimer & Co. Inc. (“Oppenheimer”). Each of Cantor, Baird and Oppenheimer are individually an “Agent” and collectively are the “Agents” under the Agreement. Also On May 19, 2021, the Company commenced an at-the-market offering (the “2021 ATM Offering”) pursuant to which the Company could sell from time to time, at its option, up to an aggregate of \$100.0 million shares of the Company’s common stock. The aggregate compensation payable to the Agents was 3.0% of the aggregate gross proceeds from each sale of the Company’s common stock.

Sales during the six months ended June 30, 2021, under the 2021 and 2020 ATM Offering are as follows (in thousands, except for share and per share amounts):

| | Six Months Ended June 30, 2021 | | |
|-----------------------------------|---|-----------------|--------------|
| | 2021 ATM | 2020 ATM | Total |
| Total shares of common stock sold | 331,811 | 19,120,037 | 19,451,848 |
| Average price per share | \$ 3.47 | \$ 1.47 | \$ 1.50 |
| Gross proceeds | \$ 1,152 | \$ 28,100 | \$ 29,252 |
| Commission earned by Sales Agents | \$ 34 | \$ 843 | \$ 877 |
| Net proceeds | \$ 1,118 | \$ 27,257 | \$ 28,375 |

2021 Exercise of Warrants. During the six months ended June 30, 2021, certain holders of our Series B, C and D warrants to purchase shares of our common stock exercised such warrants for aggregate proceeds to the Company of \$30.6 million.

2022 ATM Offering. On March 18, 2022, the Company entered a Controlled Equity Offering Sales Agreement (the “2022 Sales Agreement”), with Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc. The Company commenced an at-the-market offering (the “2022 ATM Offering”) pursuant to which the Company could sell from time to time, at its option, up to an aggregate of \$100.0 million shares of the Company’s common stock. No sales of common stock were made under the 2022 ATM Offering during the six months ended June 30, 2022.

13. Basic and Diluted Net Loss per Share

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all potential dilutive common shares that were outstanding during the period when the effect is dilutive. Potential dilutive common shares consist of incremental shares issuable upon exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding common shares figures for the three and six months ended June 30, 2022 or 2021 as the assumed exercise of outstanding options, warrants and restricted stock units would be anti-dilutive.

Potential common shares not included in calculating diluted net loss per share are as follows:

| | June 30, | |
|----------------------------------|-----------------|-------------|
| | 2022 | 2021 |
| Stock options | 7,112,573 | 4,279,335 |
| Stock warrants | 1,120,300 | 1,016,383 |
| Nonvested restricted stock units | 7,985,275 | 1,768,861 |
| Total | 16,218,148 | 7,064,579 |

14. Commitments and Contingencies

License and Supply Agreements

As part of the Company’s acquisition of the Senhance System in 2015, the Company assumed certain license and supply agreements. Additionally, the Company has purchase orders with various suppliers for certain tooling, supplies, contract engineering and research services. Commitments related to these agreements and purchase orders are as follows (in thousands):

| Fiscal Year | |
|--------------------|-----------|
| 2022 | \$ 8,465 |
| 2023 | 852 |
| 2024 | 550 |
| 2025 | 339 |
| 2026 | - |
| Thereafter | - |
| Total commitments | \$ 10,206 |

15. Segments and Geographic Areas

The Company operates in one business segment—the research, development, and sale of medical device robotics to improve minimally invasive surgery. The Company’s chief operating decision maker (determined to be the Chief Executive Officer), does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

The following table presents consolidated assets and long-lived assets by geographic area, which includes property and equipment, intellectual property, and operating lease assets:

| | June 30, 2022 | |
|-------------------|--------------------------|---------------------|
| | Long-Lived Assets | Total Assets |
| U.S. | 33% | 77% |
| EMEA | | |
| Switzerland | 40% | 18% |
| Italy | 20% | 3% |
| Other | 7% | 1% |
| Total EMEA | 67% | 22% |
| Asia | 0% | 1% |
| Total | 100% | 100% |

| | December 31, 2021 | |
|-------------------|--------------------------|---------------------|
| | Long-Lived Assets | Total Assets |
| U.S. | 26% | 77% |
| EMEA | | |
| Switzerland | 34% | 16% |
| Italy | 36% | 5% |
| Other | 4% | 1% |
| Total EMEA | 74% | 22% |
| Asia | 0% | 1% |
| Total | 100% | 100% |

The Company recognizes sales by geographic area based on the country in which the customer is based. For the three months ended June 30, 2022 and 2021, 15% and 25%, respectively, of net revenue were generated in the United States; while 63% and 53%, respectively, were generated in Europe; and 22% and 22% were generated in Asia. For the six months ended June 30, 2022 and 2021, 19% and 17%, respectively, of net revenue were generated in the United States; while 56% and 32%, respectively, were generated in Europe; and 25% and 51% were generated in Asia.

16. Related Person Transactions

In March 2018, Asensus Surgical Europe S.à.r.l entered into a Service Supply Agreement with 1 Med S.A. for certain regulatory consulting services. Andrea Biffi, a current member of the Company’s Board of Directors, owns a non-controlling interest in 1 Med S.A. Expenses under the Service Supply Agreement were approximately \$68,000 and \$0 for the three months ended June 30, 2022 and 2021, respectively and \$141,000 and \$93,000 for the six months ended June 30, 2022 and 2021, respectively.

Item 2. Management's Discussion and Analysis of Financial Conditions and Results of Operation

The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes to our condensed consolidated financial statements included in this report. The following discussion contains forward-looking statements. See cautionary note regarding "Forward-Looking Statements" at the beginning of this report.

Overview

Asensus Surgical is a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™, or ISU™, to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. The Company is focused on the market development for and commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery, or MIS. The Senhance System is the first and only digital, multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including 3mm microlaparoscopic instruments, 5mm articulating instruments, eye-sensing camera control and fully-reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.

The Senhance System is available for sale in Europe, the United States, Japan, Taiwan, Russia (to the extent lawful), and select other countries.

- The Senhance System has a CE Mark in Europe for adult and pediatric laparoscopic abdominal and pelvic surgery, as well as limited thoracic surgeries excluding cardiac and vascular surgery.
- In the United States, the Company has received 510(k) clearance from the FDA for use of the Senhance System in general laparoscopic surgical procedures and laparoscopic gynecologic surgery in a total of 31 indicated procedures, including benign and oncologic procedures, laparoscopic inguinal, hiatal and paraesophageal hernia, sleeve gastrectomy and laparoscopic cholecystectomy surgery.
- In Japan, the Company has received regulatory approval and reimbursement for 98 laparoscopic procedures.
- The Senhance System received its registration certificate by the Russian medical device regulatory agency, Roszdravnadzor, in December 2020, allowing for its sale and utilization throughout the Russian Federation.

We also enter into lease arrangements with certain qualified customers. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System during or at the end of the lease term ("Lease Buyout").

On February 23, 2021, we changed our name from TransEnterix, Inc. to Asensus Surgical, Inc. as part of our strategy to utilize the Senhance System and ISU capabilities, along with our other augmented intelligence related offerings and instrumentation to unlock clinical intelligence to enable consistently superior outcomes and a new standard of surgery we are calling Performance-Guided Surgery. We believe our product offerings, and our digitization of the interface between the surgeon and the patient allows us to assist the surgeon in all aspects of laparoscopic surgery including:

- Pre-operative - in what we call "intelligent preparation," our machine learning models will take data from all the procedures done utilizing our current Senhance System with the ISU, such as tracking surgical motion and team interaction, to create a large and constantly improving database of surgeries and their outcomes to enable surgeons to best inform their approach and surgical setup.
- Intra-operative – we believe the Senhance System provides perceptive real-time guidance for intra-operative tasks, allowing any surgeon performing a procedure with the Senhance System to perform multiple tasks and benefit from the collective knowledge and rules-based performance of thousands of other successful Senhance-based procedures. Not only will this provide the surgeon with a pathway to better outcomes, but we also believe it will ultimately help reduce the cognitive load of the surgeons.

- Post-operative – by tapping into the vast amount of data captured during procedures, surgeons and operating room staff will be able to get actionable assessments of their performance giving them the information needed to improve performance over time. We intend to establish a new standard of analytics to improve not only the skills of all surgeons but move towards best-practice-sharing that bridges the global surgeon community.

We received FDA clearance in March 2020 for our ISU. We believe it is the only FDA cleared device for machine vision technology in abdominal robotic surgery. On September 23, 2020, we announced the first surgical procedures successfully completed using the ISU. In January 2021, we received CE Mark for the ISU.

In February 2020, we received CE Mark for the Senhance System and related instruments for pediatric use indications in CE Mark territories.

In 2020, we obtained regulatory clearance for the Senhance ultrasonic system in both Taiwan and Japan. We also received clearance for the ISU in both the U.S. and Japan. Finally, in the EU, we expanded our claims for the Senhance System to include pediatric patients, allowing accessibility to more surgeons and patients, as well as expanding our potential market to include pediatric hospitals in Europe. We anticipate the robotic precision provided by the Senhance System, coupled with the already available 3mm instruments will prove to be an effective tool in surgery with smaller patients.

On July 28, 2021, the Company announced that it received FDA clearance for 5mm diameter articulating instruments, offering better access to difficult-to-reach areas of the anatomy by providing two additional degrees of freedom. These instruments have previously received CE Mark for use in the EU.

The Company believes that future outcomes of minimally invasive laparoscopic surgery will be enhanced through its combination of more advanced tools and robotic functionality, which are designed to: (i) empower surgeons with improved precision, dexterity and visualization; (ii) improve patient satisfaction and enable a desirable post-operative recovery; and (iii) provide a cost-effective robotic system, compared to existing alternatives today, for a wide range of clinical indications.

From our inception, we devoted a substantial percentage of our resources to research and development and start-up activities, consisting primarily of product design and development, clinical studies, manufacturing, recruiting qualified personnel and raising capital. We expect to continue to invest in research and development and market development as we implement our strategy.

Since inception, we have been unprofitable. As of June 30, 2022, we had an accumulated deficit of \$824.1 million. We operate in one business segment.

Recent Financing Transactions

At-the -Market Offerings

On March 18, 2022, the Company entered a Controlled Equity Offering Sales Agreement (the “2022 Sales Agreement”), with Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc. The Company commenced an at-the-market offering (the “2022 ATM Offering”) pursuant to which the Company could sell from time to time, at its option, up to an aggregate of \$100.0 million shares of the Company’s common stock. No sales of common stock were made under the 2022 ATM Offering during the six months ended June 30, 2022.

Results of Operations - Comparison of Three Months Ended June 30, 2022 and 2021

Revenue

In the second quarter of 2022, our revenue consisted of ongoing System leasing payments, sales of instruments and accessories, and services revenue for Systems sold or placed in Europe, Asia, and the U.S. in prior periods.

Product revenue for the three months ended June 30, 2022 decreased to \$0.3 million compared to \$0.4 million for the three months ended June 30, 2021. Service revenue remained consistent at \$0.4 million for the three months ended June 30, 2022 and 2021. Lease revenue remained consistent at \$0.3 million for the three months ended June 30, 2022 and 2021. The fluctuations in revenue for the three months ended June 30, 2022 and 2021, were primarily the result of customer mix and fluctuations in exchange rates.

Cost of Revenue

Cost of revenue consists of contract manufacturing, materials, labor, and manufacturing overhead incurred internally to produce the products. Shipping and handling costs incurred by the Company are included in cost of revenue. We expense all inventory obsolescence provisions as cost of revenue. The manufacturing overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment depreciation and operations supervision and management. We expect overhead costs as a percentage of revenues to decline as our production volume increases. We expect cost of revenue to increase in absolute dollars to the extent our revenues grow and as we continue to invest in our operational infrastructure to support anticipated growth.

Product cost for the three months ended June 30, 2022 decreased to \$0.9 million as compared to \$1.0 million for the three months ended June 30, 2021. The \$0.1 million decrease primarily relates to a decrease in personnel-related costs.

Service cost remained consistent at \$0.6 million for the three months ended June 30, 2022 and 2021.

Lease cost for the three months ended June 30, 2022 increased to \$0.8 million as compared to \$0.7 million for the three months ended June 30, 2021.

Research and Development

Research and development, or R&D, expenses primarily consist of engineering, product development and regulatory expenses incurred in the design, development, testing and enhancement of our products and legal services associated with our efforts to obtain and maintain broad protection for the intellectual property related to our products. In future periods, we expect R&D expenses to continue to increase as we continue to invest in additional regulatory approvals as well as new products, instruments, and accessories to be offered with the Senhance System. R&D expenses are expensed as incurred.

R&D expenses for the three months ended June 30, 2022 increased 78% to \$7.3 million as compared to \$4.1 million for the three months ended June 30, 2021 as we continue to invest in basic research, clinical studies, and product development in the areas of robotics and digital technologies supporting the growth of the Senhance System and ISU digital and cloud capabilities. All activities are in the effort of building the future for Performance-Guided Surgery. The \$3.2 million increase primarily relates to increased personnel costs of \$1.5 million driven by additional headcount as well as the transfer of employees within functional areas due to the evolving nature and commercialization of our business. The change was also driven by an increase in contract engineering services, consulting, and other outside services of \$1.0 million, increased supplies costs of \$0.3 million, and increased miscellaneous costs of \$0.4 million.

Sales and Marketing

Sales and marketing expenses include costs for sales and marketing personnel, travel, demonstration product, market development, physician training, tradeshows, marketing clinical studies and consulting expenses.

Sales and marketing expenses for the three months ended June 30, 2022 and 2021 remained consistent at \$3.6 million.

General and Administrative

General and administrative expenses consist of personnel costs related to the executive, finance, legal and human resource functions, as well as professional service fees, legal fees, accounting fees, insurance costs, and general corporate expenses.

General and administrative expenses for the three months ended June 30, 2022 increased 32% to \$5.0 million compared to \$3.8 million for the three months ended June 30, 2021. The \$1.2 million increase was primarily related to increased personnel costs of \$1.0 million driven by additional headcount as well as the transfer of employees within functional areas due to the evolving nature and commercialization of our business. The change was also driven by an increase in miscellaneous costs of \$0.5 million, partially offset by a decrease in bad debt expense of \$0.2 million, and a decrease in supplies costs of \$0.1 million.

Amortization of Intangible Assets

Amortization of intangible assets for the three months ended June 30, 2022 decreased to \$2.5 million compared to \$2.9 million for the three months ended June 30, 2021. The \$0.4 million decrease is primarily driven by changes in the foreign currency exchange rate.

Change in Fair Value of Contingent Consideration

The change in fair value of contingent consideration in connection with the Senhance Acquisition was a \$0.6 million decrease for the three months ended June 30, 2022 compared to a \$0.5 million increase for the three months ended June 30, 2021. The decrease was primarily due to changes in market assumptions utilized in the valuation of fair value of the contingent consideration.

Property and Equipment Impairment

During the three months ended June 30, 2022, the Company recorded an impairment charge of \$0.4 million to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment is associated with operating leases that did not elect to renew their agreements. No impairment charge was recognized for the three months ended June 30, 2021.

Other Income (Expense)

Other income for the three months ended June 30, 2022 decreased to \$0.0 million compared to \$2.9 million for the three months ended June 30, 2021. Other income for the three months ended June 30, 2021 primarily related to the gain on extinguishment of debt of \$2.8 million. No related income was recorded in the three months ended June 30, 2022.

Income Tax (Expense) Benefit

The Company recognized \$0.1 million income tax expense for the three months ended June 30, 2022, compared to \$0.0 million income tax expense for the three months ended June 30, 2021.

Results of Operations - Comparison of Six Months Ended June 30, 2022 and 2021

Revenue

In the six months ended June 30, 2022, our revenue consisted of ongoing System leasing payments, sales of instruments and accessories, and services revenue for Systems sold or placed in Europe, Asia, and the U.S. in prior periods.

Product revenue for the six months ended June 30, 2022 decreased to \$0.6 million compared to \$1.7 million for the six months ended June 30, 2021. The \$1.1 million decrease was primarily the result of a Lease Buyout in the prior period.

Service revenue for the six months ended June 30, 2022 decreased to \$0.7 million compared to \$0.8 million for the six months ended June 30, 2021. The \$0.1 million decrease was the result of customer mix and fluctuations in exchange rates.

Lease revenue for the six months ended June 30, 2022 and 2021 remained consistent at \$0.7 million.

Cost of Revenue

Cost of revenue consists of contract manufacturing, materials, labor, and manufacturing overhead incurred internally to produce the products. Shipping and handling costs incurred by the Company are included in cost of revenue. We expense all inventory obsolescence provisions as cost of revenue. The manufacturing overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment depreciation and operations supervision and management. We expect overhead costs as a percentage of revenues to decline as our production volume increases. We expect cost of revenue to increase in absolute dollars to the extent our revenues grow and as we continue to invest in our operational infrastructure to support anticipated growth.

Product cost for the six months ended June 30, 2022 decreased to \$1.3 million as compared to \$2.7 million for the six months ended June 30, 2021. The \$1.4 million decrease primarily relates to a \$0.7 million decrease in product costs driven by a Lease Buyout in the prior period and a \$0.9 million decrease in personnel-related costs, partially offset by a \$0.1 million increase in supplies costs and \$0.1 million increase in freight expenses.

Service cost for the six months ended June 30, 2022 increased to \$1.1 million as compared to \$1.0 million for the six months ended June 30, 2021. The \$0.1 million increase primarily relates to an increase in personnel-related costs. Cost of revenue exceeds revenue primarily due to part replacements under maintenance plans, which are expensed when incurred, along with salaries for the field service teams.

Lease cost for the six months ended June 30, 2022 and 2021 remained consistent at \$1.8 million.

Research and Development

Research and development, or R&D, expenses primarily consist of engineering, product development and regulatory expenses incurred in the design, development, testing and enhancement of our products and legal services associated with our efforts to obtain and maintain broad protection for the intellectual property related to our products. In future periods, we expect R&D expenses to continue to increase moderately as we continue to invest in additional regulatory approvals as well as new products, instruments and accessories to be offered with the Senhance System. R&D expenses are expensed as incurred.

R&D expenses for the six months ended June 30, 2022 increased 65% to \$13.7 million as compared to \$8.3 million for the six months ended June 30, 2021 as we continue to invest in basic research, clinical studies, and product development in the areas of robotics and digital technologies supporting the growth of the Senhance System and ISU digital and cloud capabilities. All activities are in the effort of building the future for Performance-Guided Surgery. The \$5.4 million increase primarily relates to increased personnel costs of \$2.5 million driven by additional headcount as well as the transfer of employees within functional areas due to the evolving nature and commercialization of our business. The change was also driven by an increase in contract engineering services, consulting, and other outside services costs of \$1.9 million, increased supplies costs of \$0.4 million, and increased miscellaneous costs of \$0.6 million.

Sales and Marketing

Sales and marketing expenses include costs for sales and marketing personnel, travel, demonstration product, market development, physician training, tradeshows, marketing clinical studies and consulting expenses.

Sales and marketing expenses for the six months ended June 30, 2022 increased 11% to \$7.3 million compared to \$6.6 million for the six months ended June 30, 2021. The \$0.7 million increase was primarily related to increased consulting costs of \$0.5 million, increased travel costs of \$0.5 million, partially offset by decreased supplies costs of \$0.3 million.

General and Administrative

General and administrative expenses consist of personnel costs related to the executive, finance, legal and human resource functions, as well as professional service fees, legal fees, accounting fees, insurance costs, and general corporate expenses.

General and administrative expenses for the six months ended June 30, 2022 increased 35% to \$10.5 million compared to \$7.8 million for the six months ended June 30, 2021. The \$2.7 million increase was primarily related to increased personnel costs of \$1.9 million driven by additional headcount as well as the transfer of employees within functional areas due to the evolving nature and commercialization of our business. The change was also driven by an increase in software costs of \$0.4 million, increased consulting costs of \$0.2 million, and increased miscellaneous costs of \$0.2 million.

Amortization of Intangible Assets

Amortization of intangible assets for the six months ended June 30, 2022 decreased to \$5.2 million compared to \$5.7 million for the six months ended June 30, 2021. The \$0.5 million decrease is primarily driven by changes in the foreign currency exchange rate.

Change in Fair Value of Contingent Consideration

The change in fair value of contingent consideration in connection with the Senhance Acquisition was a \$0.8 million decrease for the six months ended June 30, 2022 compared to a \$0.7 million increase for the six months ended June 30, 2021. The decrease was primarily due to changes in market assumptions utilized in the valuation of fair value of the contingent consideration.

Property and Equipment Impairment

During the six months ended June 30, 2022, the Company recorded an impairment charge of \$0.4 million to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment is associated with operating leases that did not elect to renew their agreements. No impairment charge was recognized for the six months ended June 30, 2021.

Other Income (Expense)

The Company recognized \$0.1 other expense for the six months ended June 30, 2022, compared to \$0.9 million other income for the six months ended June 30, 2021. Other income for the six months ended June 30, 2021 primarily related to the gain on extinguishment of debt of \$2.8 million, partially offset by the change in the fair value of Series B Warrants of \$2.0 million. No related income or expense was recorded in the six months ended June 30, 2022.

Income Tax (Expense) Benefit

The Company recognized \$0.2 million income tax expense for the six months ended June 30, 2022, compared to \$0.0 million income tax benefit for the six months ended June 30, 2021.

Liquidity and Capital Resources

The Company had an accumulated deficit of \$824.1 million and working capital of \$98.9 million as of June 30, 2022. The Company has not established sufficient revenues to cover its operating costs and believes it will require additional capital in the future to proceed with its operating plan. As of June 30, 2022, the Company had cash, cash equivalents, short-term investments and long-term investments, excluding restricted cash, of approximately \$103.8 million.

The Company believes the COVID-19 pandemic and other geopolitical factors will continue to negatively impact its operations and ability to implement its market development efforts, which will have a negative effect on its financial condition.

While the Company believes that its existing cash, cash equivalents, short-term and long-term investments, as of June 30, 2022 and as of the date of filing, will be sufficient to sustain operations for at least the next 12 months from the issuance of these financial statements, the Company believes it will need to obtain additional financing in the future to proceed with its business plan. Management's plan to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans.

The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: negative impacts on the Company's operations caused by the COVID-19 pandemic and other geopolitical factors; the historical lack of profitability; the Company's ability to increase utilization of the Senhance System and grow its placements, the Company's ability to raise additional capital; the success of its market development efforts; its ability to successfully develop, clinically test and commercialize its products; the timing and outcome of the regulatory review process for its products; changes in the health care and regulatory environments of the United States, the European Union, Japan, Taiwan and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution concern; competition in the market for robotic surgical devices; and its ability to identify and pursue development of additional products.

Sources of Liquidity

Our principal sources of cash to date have been proceeds from public offerings of common stock, incurrence of debt, the sale of equity securities held as investments and asset sales.

Consolidated Cash Flow Data

| (Unaudited, in millions) | Six Months Ended June 30, | |
|---|----------------------------------|-----------------|
| | 2022 | 2021 |
| Net cash (used in) provided by | | |
| Operating activities | \$ (30.2) | \$ (18.5) |
| Investing activities | 23.2 | (0.7) |
| Financing activities | (0.3) | 160.1 |
| Effect of exchange rate changes on cash and cash equivalents | 0.2 | (0.3) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | <u>\$ (7.1)</u> | <u>\$ 140.6</u> |

Operating Activities

For the six months ended June 30, 2022, cash used in operating activities of \$30.2 million consisted of a net loss of \$38.7 million, changes in operating assets and liabilities of \$2.6 million, offset by non-cash items of \$11.1 million. The non-cash items primarily consisted of \$5.2 million of amortization of intangible assets, \$4.3 million of stock-based compensation expense, \$1.7 million of depreciation, \$0.4 million of net amortization of discounts and premiums on investments, \$0.4 million in impairment of property and equipment, \$0.2 million deferred tax expense, offset by \$0.6 million change in inventory reserves and \$0.8 million of change in fair value of contingent consideration. The decrease in cash from changes in operating assets and liabilities primarily relates to a \$1.9 million increase in inventory net of transfers to property and equipment, \$1.2 million increase in other current and long-term assets, \$0.3 million decrease in accrued expenses, \$0.3 million decrease in operating lease liabilities, offset by a \$0.5 million increase in accounts payable, \$0.4 million decrease in operating lease right-of-use assets, and a \$0.2 million decrease in prepaid expenses.

For the six months ended June 30, 2021, cash used in operating activities of \$18.5 million consisted of a net loss of \$30.5 million offset by cash generated from work capital of \$1.0 million and non-cash items of \$11.1 million. The non-cash items primarily consisted of \$3.6 million of stock-based compensation expense, \$5.7 million of amortization of intangible assets, \$2.0 million change in fair value of warrant liabilities, \$1.6 million of depreciation, \$0.7 million change in fair value of contingent consideration, and \$0.3 million change in inventory reserves, offset by \$2.8 million gain on extinguishment of debt. The increase in cash from changes in working capital primarily relates to a \$3.1 million increase in operating lease liabilities, a \$2.7 million decrease in other current and long-term assets, a \$0.7 million increase in accounts payable, a \$0.5 million decrease in prepaid expenses, and a \$0.1 million decrease in accounts receivable, offset by a \$3.0 million increase in operating lease right-of-use asset, a \$1.7 million increase in inventory net of transfers of property and equipment, and a \$1.4 million decrease in accrued expenses.

Investing Activities

For the six months ended June 30, 2022, net cash provided by investing activities was \$23.2 million. This amount consists of \$41.4 million of proceeds from maturities of available-for-sale investments, offset by \$17.8 million of purchases of available-for-sale investments and \$0.4 million purchases of property and equipment.

For the six months ended June 30, 2021, net cash used in investing activities was \$0.7 million, related to purchases of property and equipment.

Financing Activities

For the six months ended June 30, 2022, net cash used in financing activities was \$0.3 million, related to taxes paid for the net share settlement of vesting of restricted stock units.

For the six months ended June 30, 2021, net cash provided by financing activities was \$160.1 million. The net change primarily related to \$130.3 million in net proceeds from the issuance of common stock and \$30.8 million aggregate proceeds from the exercise of Series B, C and D warrants, partially offset by \$1.0 million of taxes paid related to net share settlement of vesting of restricted stock units.

Operating Capital and Capital Expenditure Requirements

We intend to spend substantial amounts on research and development activities, including product development, regulatory and compliance, and clinical studies. We intend to use financing opportunities strategically to continue to strengthen our financial position.

Cash and cash equivalents held by our foreign subsidiaries totaled \$2.4 million as of June 30, 2022, including restricted cash. We do not intend or currently foresee a need to repatriate cash and cash equivalents held by our foreign subsidiaries. If these funds are needed in the United States, we believe that the potential U.S. tax impact to repatriate these funds would be immaterial.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations set forth above under the headings “Results of Operations” and “Liquidity and Capital Resources” have been prepared in accordance with U.S. GAAP and should be read in conjunction with our financial statements and notes thereto appearing in this Form 10-Q and in the Fiscal 2021 Form 10-K. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our critical accounting policies and estimates, including identifiable intangible assets, contingent consideration, stock-based compensation, inventory, revenue recognition and income taxes. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. A more detailed discussion on the application of these and other accounting policies can be found in Note 2 in the Notes to the Financial Statements in this Form 10-Q. Actual results may differ from these estimates under different assumptions and conditions. There have been no new or material changes to the critical accounting estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, that are of significance, or potential significance, to us.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to changes in foreign currency exchange rates. Operations outside of the United States accounted for 81% and 83% of revenue for six months ended June 30, 2022 and 2021, respectively, and are concentrated principally in Europe. We translate the revenue and expenses of our foreign operations using average exchange rates prevailing during the period. The effect of a 10% change in the average foreign currency exchange rates among the U.S. dollar versus the Euro for the six months ended June 30, 2022, would result in revenue changing by \$0.2 million. This change would be not material to our cash flows and our results of operations.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2022. We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Executive Vice President and Chief Financial Officer concluded that, as of June 30, 2022, our disclosure controls and procedures were effective at a reasonable assurance level.

Changes in Internal Controls Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that some of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.

PART II. OTHER INFORMATION

Item 1 Legal Proceedings.

None.

Item 1A Risk Factors.

Reference is made to the Risk Factors included in our Fiscal 2021 Form 10-K. There have been no material changes to our risk factors from those disclosed under "Risk Factors" in Part I, Item 1A of our Fiscal 2021 Form 10-K, which are supplemented by the following:

We continue to see the impact of the COVID-19 pandemic and other geopolitical factors on our business, and cannot assure you that we will be able to grow our business as forecast.

We continue to see delays in implementing robotic systems, training physicians on the use of the Senhance System and working with hospitals and surgeons to increase procedure volumes because of the impact of the COVID-19 pandemic, related world-wide supply shortages and the ongoing war in the Ukraine, as well as other geopolitical factors. We cannot assure you that we can implement our growth plans on the timeline desired, and continued delays could have a material negative impact on our business, results of operations and financial condition.

We may experience difficulties implementing our new global enterprise resource planning system.

We are engaged in a multi-year implementation of a new global enterprise resource planning system ("ERP"), which is entering a critical phase in 2022. The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. In addition, our efforts to centralize various business processes and functions within our organization in connection with our ERP implementation may continue to disrupt our operations and negatively impact our business, results of operations and financial condition.

Many of our Senhance Systems are placed under leasing arrangements with a buy-out option. If the customer does not extend the leasing arrangement or elect to purchase the Senhance System, it reduces future revenue.

Many of our Senhance Systems are placed under leasing arrangements with a buy-out option. If the customer does not elect to extend the lease arrangement or purchase the Senhance System it is returned to us, which reduces future revenue as we will not receive revenues from the capital purchases. In the quarter ended June 30, 2022, four customers chose not to extend their lease arrangements. As our leasing arrangements expire, we may see a termination of more leasing arrangements, which could have a material impact on our future revenues.

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3 Defaults Upon Senior Securities.

None.

Item 4 Mine Safety Disclosures.

Not applicable.

Item 5 Other Information.

None.

Item 6. EXHIBITS

| Exhibit No. | Description |
|--------------------|--|
| 31.1 * | Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a). |
| 31.2 * | Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a). |
| 32.1 * | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2 * | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS * | Inline XBRL Instance Document. |
| 101.SCH* * | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL* * | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF* * | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB* * | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE * | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline XBRL (included in Exhibit 101). |

* Filed herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Asensus Surgical, Inc.

Date: August 8, 2022

By: /s/ Anthony Fernando
Anthony Fernando
President and Chief Executive Officer

Date: August 8, 2022

By: /s/ Shameze Rampertab
Shameze Rampertab
Executive Vice President and Chief Financial Officer

SECTION 302
CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Anthony Fernando, certify that:

- (1) I have reviewed this Quarterly Report on Form 10-Q of Asensus Surgical, Inc.;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- (4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- (5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

August 8, 2022

By: /s/ Anthony Fernando
Anthony Fernando,
President and Chief Executive Officer
(Principal Executive Officer)

**SECTION 302
CERTIFICATION OF CHIEF FINANCIAL OFFICER**

I, Shameze Rampertab, certify that:

- (1) I have reviewed this Quarterly Report on Form 10-Q of Asensus Surgical, Inc.;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- (4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- (5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

August 8, 2022

By: /s/ Shameze Rampertab
Shameze Rampertab
Executive Vice President and Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Anthony Fernando, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and 18 U.S.C. Section 1350, that the Quarterly Report on Form 10-Q of Asensus Surgical, Inc. (the “Company”) for the quarterly period ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /s/ Anthony Fernando

/s/ Anthony Fernando

Anthony Fernando, President and Chief Executive Officer (Principal Executive Officer)

August 8, 2022

The certification set forth above is being furnished as an Exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report or as a separate disclosure document of Asensus Surgical, Inc. or the certifying officers.

**CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Shameze Rampertab, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and 18 U.S.C. Section 1350, that the Quarterly Report on Form 10-Q of Asensus Surgical, Inc. (the “Company”) for the quarterly period ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /s/ Shameze Rampertab

/s/ Shameze Rampertab

Shameze Rampertab, Executive Vice President and Chief Financial Officer (Principal Financial Officer
and Principal Accounting Officer)

August 8, 2022

The certification set forth above is being furnished as an Exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report or as a separate disclosure document of Asensus Surgical, Inc. or the certifying officers.